Small Molecule Therapeutics NT 113 , a Pan-ERBB Inhibitor with High Brain Penetrance , Inhibits the Growth of Glioblastoma Xenografts with EGFR Ampli fi cation
暂无分享,去创建一个
C. James | J. Sarkaria | N. Butowski | J. Raizer | A. Mazar | A. Stegh | T. Ozawa | F. Giles | Shi-Yuan Cheng | A. Parsa | T. Nicolaides | Y. Yoshida | Tsun‐Wen Yao | W. Shen | Dennis Brown
[1] N. Gottardo,et al. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. , 2014, Oncogene.
[2] Susan M. Chang,et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. , 2014, Neuro-oncology.
[3] L. Deangelis,et al. Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.
[4] Ivan Babic,et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.
[5] O. Politz,et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models , 2012, Investigational New Drugs.
[6] G. Riggins,et al. Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy , 2012, PloS one.
[7] Paul S Mischel,et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.
[8] K. Roth,et al. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells. , 2012, Neuro-oncology.
[9] D. Housman,et al. Acquired MET Expression Confers Resistance to EGFR Inhibition In a Mouse Model of Glioblastoma Multiforme , 2011, Oncogene.
[10] C. Wirtz,et al. Erlotinib in glioblastoma: lost in translation? , 2011, Anti-cancer agents in medicinal chemistry.
[11] W. Mason,et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. James,et al. Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging , 2010, Journal of visualized experiments : JoVE.
[13] S. Keir,et al. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program , 2009, Pediatric blood & cancer.
[14] J. Gallo,et al. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib , 2009, Molecular Cancer Therapeutics.
[15] M. Berger,et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. , 2007, Journal of neurosurgery.
[16] J. Panetta,et al. Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 , 2007, Clinical Cancer Research.
[17] C. James,et al. Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.
[18] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[19] C. James,et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.
[20] Caterina Giannini,et al. Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.
[21] K. Aldape,et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.
[22] D. W. Fry,et al. Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition* , 2001, The Journal of Biological Chemistry.
[23] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[24] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[25] C. James,et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.
[26] Susan M. Chang,et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.
[27] Amy E. Hawkins,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2022 .